July 18: 2023 Brings Multiple Waves of Additional Studies Regarding Mesotheliomas and Other Cancers Caused Solely by Genomic Factors

Topics for discussion include:

• The Big Picture Status of Genomics in Mesothelioma Litigation
• Recent Statistical Analyses of Genetically Engineered Mice Reject BAP1 “Susceptibility” Arguments
• Recent Papers Further Confirm Genomic Abnormalities are the Sole Cause of Some Mesotheliomas
• Stakeholders on Trial Preference Motions Need to Understand Recent Studies Showing Why Persons with Some BAP1 Mutations Are in Fact Living for Many Years
• Recently Papers Provide Further Information Regarding the Frequency and Pathogenicity Genetics of Mesotheliomas and Other Cancers
• Software for Predicting Pathogenicity is Providing Quantitative Assessments of Germline Mutations in Cancer Associated Genes – CADD Methods and Results
• Tumor Sequencing Data Frequently Exists - Don’t Miss Large Amounts of Valuable Sequencing Data that Is Not Shown in Paper Reports
• The Cost/Benefit Analysis of Whole Genome Sequencing Versus Targeted Panels - Understanding the Strengths and Limitations in Your Cases.

Title:

2023 Brings Multiple Waves of Additional Studies Regarding Mesotheliomas and Other Cancers Caused Solely by Genomic Factors

Date+Time:
July 18, 2023
2:00-3:30 p.m. ET

Register Now for this free Continuing Legal Education Webinar!
Speakers:

• Kirk T. Hartley, Principal at LSP Group and ToxicoGenomica
• Leonel van Zyl, PhD., ToxicoGenomica, CEO, ArrayXpress Inc.
• Michael Zapata III, Executive Chairman, ArrayXpress, Inc. and Protochips Inc.

CLE Credit:

California, Illinois, New Jersey, New York, Pennsylvania, Texas.

By:

Perrin Conferences.

More Information And Registration